Abbott opts to resolve ongoing litigation regarding premature infant formula by agreeing to a $670 million settlement.

ABT · Abbott Laboratories

The AI's read

Abbott agreed to settle the Gill case plus about 2,000 NEC claims for $670 million, bypassing further appeals and capping a headline legal exposure. That matters because it removes a major legal overhang for a $197B company and shortens a long-running uncertainty. The market barely reacted, down 0.33% and RSI at 53.98, so the news does not look fully priced in. The payout is meaningful headline-wise but small versus market cap and expected damages plus interest. We lean positive: the settlement buys clarity, limits future interest accrual, and lets management focus on core growth. Main caveat is the roughly 1,700 remaining lawsuits covering 12,700 infants, which still add uncertainty but look manageable versus this payout.